Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech Forms Pre-Clinical Collaboration with Janssen

publication date: Mar 2, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech (药明康德) has struck a two-way pre-clinical services deal with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. WuXi PharmaTech will provide toxicology and other non-clinical services to Janssen, while Janssen will help WuXi attain GLP status in its new Suzhou toxicology lab. More details...

Stock Symbol: (NYSE: WX)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors